Capricor Therapeutics Shares Drop Despite Positive Deramiocel OLE Data
Capricor Therapeutics (CAPR) saw its stock fall by approximately 10% in Monday trading, despite the release of positive data from a two-year crossover analysis for deramiocel, an investigational therapy targeting Duchenne muscular dystrophy. The open-label extension study showed encouraging results; however, investors remain skeptical about whether these findings will be sufficient to secure approval from the U.S. Food and Drug Administration (FDA). The mixed market reaction highlights ongoing concerns regarding regulatory hurdles for deramiocel despite clinical progress. While the data may support continued development of the drug candidate, uncertainty around FDA acceptance has led investors to take a cautious stance. Capricor's stock performance underscores investor sentiment that remains sensitive to perceived risks in late-stage regulatory pathways.
Tickers: $CAPR
Topics: clinical trial results investor sentiment stock price movement